UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the second quarter that ended June 30, 2022 and provided a business update.
- We believe the favorable safety profile of Zeno may also allow for future, potential benefit in combination with other cancer therapies.
- Details of the eNRGy trial can be found at www.ClinicalTrials.gov and Merus trial website at www.nrg1.com ,or by calling 1-833-NRG-1234.
- As of June 30, 2022, Merus had $396.8 million cash and cash equivalents sufficient to fund company operations beyond 2024.
- We ended the second quarter with cash, cash equivalents and marketable securities of $396.8 million compared to $430.7 million at December 31, 2021.